UCSF adult and pediatric clinical trials

UCSF Brain Tumor Center Clinical Trials

Our clinical trials evaluate a broad range of innovative therapies for both adults and children with brain tumors. 

Identify Relevant Clinical Trials
Clinical Trial Phase
Intervention Model
Treatment Modality
Which of the following treatments has the patient already received?*
Genetic Features*
  • Recruiting Recruiting
  • Pediatrics Pediatrics
  • On Hold On Hold
Conditions
Diffuse Midline Glioma
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Glioblastoma (grade IV)
Brainstem Glioma
Ependymoma
This phase I clinical trial will evaluate ONC206 alone or in combination with radiation therapy in treating pediatric patients with newly diagnosed or recurrent DMGs, or other recurrent primary malignant brain tumors.
Recruiting
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Diffuse astrocytoma (grade II)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Medulloblastoma
Ependymoma
This phase I clinical trial will study a novel drug called ALRN-6924 for treating children and young adults with recurrent or refractory solid tumors, brain tumors, lymphoma or leukemia. 
Recruiting
Conditions
Glioma
Glioblastoma (grade IV)

This is a phase I/II trial that aims to to establish a safe and effective dose of albumin-bound paclitaxel, to demonstrate that the opening of the blood-brain barrier increases chemotherapy concentration in the tumor, and to estimate how effective this treatment is in reducing the tumor burden and prolonging life.

Recruiting
Conditions
Glioma
Astrocytoma
Pilocytic astrocytoma (grade I)
Pleomorphic xanthoastrocytoma (grades II-III)
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Brainstem Glioma
Diffuse Midline Glioma
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Ependymoma
Medulloblastoma
Summary

This phase I/II  clinical trial will evaluate REGN2810 (also called cemiplimab) in combination with radiation therapy as a treatment for pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG), newly d

Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Pleomorphic xanthoastrocytoma (grades II-III)
Diffuse astrocytoma (grade II)
This phase I study will evaluate the safety, dose-limiting toxicities, and preliminary efficacy of vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant astrocytomas.
Recruiting
Conditions
Glioma
Astrocytoma
Anaplastic astrocytoma (grade III)
Glioblastoma (grade IV)
Pleomorphic xanthoastrocytoma (grades II-III)
Ependymoma
Medulloblastoma
Oligodendroglioma
Pilocytic astrocytoma (grade I)
Atypical Teratoid / Rhabdoid Tumor (AT/RT)
Brainstem Glioma
Diffuse Midline Glioma
Pineal Region Tumors
This phase II clinical trial tests the use of a precision medicine approach in treating pediatric patients with recurrent solid tumors, including central nervous system tumors. 
Recruiting
Conditions
Glioma
Astrocytoma
Diffuse astrocytoma (grade II)
Pleomorphic xanthoastrocytoma (grades II-III)
Pilocytic astrocytoma (grade I)
Subependymal giant cell astrocytoma (grade I)
Ependymoma
Oligodendroglioma
This phase I trial study will evaluate the dosage, safety and efficacy of trametinib and everolimus in treating pediatric and young adult patients with recurrent low-grade glioma.
Recruiting

Stay Informed